Scalable, single-use solutions for purification of viral vectors

 

I‌ndustrialization of cell and gene therapies requires robust, scalable manufacturing processes. Purification of viral vectors can be achieved using scalable, single-use technologies including direct-flow filtration (depth and sterile), membrane-based ion exchange chromatography, and tangential-flow filtration (TFF). Here we present a strategy for using these technologies from Pall for LV manufacturing platforms.

 

Speaker

Todd Sanderson

 

Sr. Manager R&D 

Pall, USA


Todd has been with Pall since 2006. He has over 20 years of research experience with expertise in mammalian cell culture, process development and analytical method development. He currently leads the Gene Therapy Upstream Cell Culture and Analytics Team in the Biotech Process R&D group. He holds a B.S. in Biochemistry and B.S. in Psychology from Michigan State University. When not at work, Todd enjoys gardening and spending time with his young children. 

Scalable, single-use solutions for purification of viral vectors

Learn about Transient transfection at large scale for clinical AAV9 vector manufacturing

Watch Rachel Legmann’s video presented during ICST 2020 Virtual event.

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
April 2022
Getting Ready for SUT X-Ray Irradiation

Biotech | Pall Corporation webinar series

Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare

 

The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.

 

Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.

 

You will learn more about:

 

  • Why this is a critical change for industry and the responsibilities of each stakeholder
  • Key questions to address for biomanufacturers
  • How gamma and X-ray irradiation compare
  • What testing has been completed and key milestones for readiness for industry
  • An example of how to qualify a SUS sterilized with X-ray irradiation
Watch